Drugs / GT005
Trials 4
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/21 trial | ||||||
| Phase 1/2 | NCT03846193 | Dec 2018 → Jun 2024 | diffuse secondary choroid atrophy, dry age related macular degeneration | Gyroscope Therapeutics Limited | Terminated | No outcome recorded |
| Phase 23 trials · 2 missed | ||||||
| Phase 2 | NCT05481827 | Jul 2022 → Jun 2028 expected | age-related macular degeneration | Gyroscope Therapeutics Limited | Enrolling by invitation | No outcome recorded |
| Phase 2 | NCT04566445 | Sep 2020 → Jun 2024 | dry age related macular degeneration | Gyroscope Therapeutics Limited | Terminated | Missed primary |
| Phase 2 | NCT04437368 | Apr 2019 → Apr 2024 | dry age related macular degeneration | Gyroscope Therapeutics Limited | Terminated | Missed primary |
Evidence & citations 5 cited values
Every value below carries the sentence it was read from. 5 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | GT005 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04566445 ↗ |
| Action | Restore | “supplementation of Complement Factor I (CFI), a key regulator of the complement system, has the potential to provide a treatment option for AMD” PMID 33750925 ↗ Mar 2021 |
| Modality | Gene therapy (AAV / viral vector) | “GT005 is a recombinant, non-replicating AAV2 expressing human complement factor I (CFI).” NCT04437368 ↗ |
| Route | Other | “GT005 was administered as a single time subretinal injection into the study eye of subjects allocated to one of the two GT005 doses.” NCT03846193 ↗ |
| Target | CFI | “GT005 is a recombinant, non-replicating AAV2 expressing human complement factor I (CFI).” NCT03846193 ↗ |